Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 4/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.66 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.66 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.66 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.66 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.66 |
| ▸ | LDHA | P00338 | 1/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
| ▸ | FBP1 | P09467 | 1/20 | 0.66 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.66 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.66 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL381173 | 1.00 | P2RY1 (0.66) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL3699269 | 0.90 | P2RY1 (0.68) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL1723484 | 0.89 | P2RY1 (0.70) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL1000175 | 0.88 | P2RY1 (0.68) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL8708990 | 0.88 | ADORA1 (0.71) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL28978257 | 0.87 | P2RY1 (0.65) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL6569310 | 0.87 | ADORA1 (0.73) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL10586180 | 0.86 | P2RY1 (0.68) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL30637132 | 0.86 | P2RY1 (0.68) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL11519682 | 0.86 | P2RY1 (0.68) | P2RY1ADORA1P2RY2SMN1; SMN2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118215490-A | T cells with cell surface expression of adenosine deaminase and uses thereof | 小利兰·斯坦福大学董事会 | 2024-06-18 | — | — | CN | disclosed |
| WO-2021084791-A1 | COMPOSITION TARGETED TO ADENOSINE A2A RECEPTOR | 有限会社イムノ | 2021-05-06 | — | — | WO | disclosed |
| EP-3182979-A1 | NOVEL COMPOSITIONS AND METHODS USEFUL FOR TREATING OR PREVENTING LIVER DISEASES OR DISORDERS, AND PROMOTING WEIGHT LOSS | Yale University (US) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016028753-A1 | NOVEL COMPOSITIONS AND METHODS USEFUL FOR TREATING OR PREVENTING LIVER DISEASES OR DISORDERS, AND PROMOTING WEIGHT LOSS | YALE UNIVERSITY (US) | 2016-02-25 | — | — | WO | disclosed |
| US-8541431-B2 | Pyrimidine non-classical cannabinoid compounds and related methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-09-24 | — | — | US | disclosed |
| US-20090286810-A1 | Pyrimidine Non-Classical Cannabinoid Compounds and Related Methods of Use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-11-19 | — | — | US | disclosed |
| EP-1045636-A4 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAILING MYOCARDIAL TISSUE | FELDMAN ARTHUR M (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6221851-B1 | INCREASING CELLULAR AVAILABILITY OF ADENOSINE. | CARDIOKINE, INC. | 2001-04-24 | — | — | US | disclosed |
| EP-1045636-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAILING MYOCARDIAL TISSUE | Feldman, Arthur M. (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-1019427-A1 | N?6 -SUBSTITUTED-ADENOSINE-5'-URONAMIDES AS ADENOSINE RECEPTOR MODULATORS | Medco Research, Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-1019427-A4 | N?6 -SUBSTITUTED-ADENOSINE-5'-URONAMIDES AS ADENOSINE RECEPTOR MODULATORS | MEDCO RES INC (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5998386-A | Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue | CARDIOKINE, INC. | 1999-12-07 | — | — | US | disclosed |
| WO-1999013721-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAILING MYOCARDIAL TISSUE | FELDMAN, ARTHUR, M. (US) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999006053-A1 | N6-SUBSTITUTED-ADENOSINE-5'-URONAMIDES AS ADENOSINE RECEPTOR MODULATORS | MEDCO RESEARCH, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0322206-B1 | Compositions and methods for improving cold tolerance in animals and humans | CA MINISTER NAT DEFENCE (CA) | 1995-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286810-A1 | Pyrimidine Non-Classical Cannabinoid Compounds and Related Methods of Use | CNR1, CNR2, GPR18 | P2RY1 12/4885ADORA1 47/4885P2RY2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.